FREMONT, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- WaferGen Bio-systems, Inc. (Nasdaq:WGBS) will present results from the Company’s single-cell analysis system at the Single Cell Genomics (SCG) Conference on September 16th, 2015, in Utrecht, The Netherlands. The presentation will highlight throughput and performance levels not previously achieved prior to the development of WaferGen’s single-cell research platform (poster abstract code P036). In addition, data generated by the Company’s single-cell early access partners utilizing WaferGen’s technology will also be presented at the conference.
Both the in-house generated results and the data produced by WaferGen’s partners will demonstrate that thousands of individual cells can be isolated and analyzed from heterogeneous cell populations which, when coupled with partitioning the chip into multiple sections, allows for powerful screening of cells for applications including therapeutic dose determination and gene insertion/deletion efficacy studies. WaferGen’s presentation, which will be given by Dr. Maithreyan Srinivasan, the Company’s Chief Technology Officer, will also include a demonstration of a first of its kind software designed specifically for selecting isolated cells for subsequent processing for RNA-Sequencing applications.
“The development of our single-cell analysis platform is progressing extremely well. The system is producing compelling data both in-house and with our world-class early access partners at Genentech, Karolinska Institutet, National Jewish Health, and MD Anderson Cancer Center. We are pleased to present late-breaking results of our program at SCG 2015, and look forward to providing additional details surrounding these results shortly,” said Rollie Carlson, President and CEO of WaferGen.
About WaferGen
WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The single cell analysis platform is a revolutionary system which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing (NGS). The SmartChip platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel single-plex PCR for one-step target enrichment and library preparation for clinical NGS. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries.
About SCG 2015
Building on the success of the single cell genomics meeting at the Karolinska Institutet in September 2014 and at the Weizmann Institute in 2013, the third Single Cell Genomics meeting will be held September 16-18, 2015, at the Hubrecht Institute in Utrecht, The Netherlands. Single cell genomics is rapidly emerging as a revolutionary technology transforming many fields of biological research. Through its many applications (single cell genome sequencing, single cell transcriptomics, various single cell epigenetic profiling approaches), researchers can characterize the genetic and functional properties of individual cells in their native conditions, leading to numerous experimental and clinical opportunities.
The conference will bring together many of the pioneers and leading experts in the field for three days of extensive, interdisciplinary and informal discussion. The meeting will include presentations from thirty invited leaders and several selected abstracts, a poster session and many opportunities for interaction. (www.weizmann.ac.il/conferences/SCG2015)
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage, our expectations regarding our development of future products including single cell analysis technologies and our expectations concerning our competitive position and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: INVESTOR CONTACTS: LifeSci Advisors, LLC Brian Ritchie BRitchie@LifeSciAdvisors.com WaferGen Bio-systems, Inc. Rollie Carlson Rollie.Carlson@wafergen.com
Help employers find you! Check out all the jobs and post your resume.
